Table 5.
Self-efficacya |
Distressb |
|||
---|---|---|---|---|
Responders (n = 23) |
Nonresponders (n = 20) |
Responders (n = 35) |
Nonresponders (n = 17) |
|
M (±SD) | M (±SD) | M (±SD) | M (±SD) | |
Caregiver | ||||
Fatigue | 2.65 (±18.6) | 6.35 (±12.9) | 1.26 (±14.1) | 10.65 (±16.5) |
Sleep | 5.71 (± 3.8)c | 6.71 (±2.9)d | 5.37 (±3.3) | 6.19 (± 2.8) |
Health behaviors | 2.70 (±0.5) | 2.42 (±0.5) | 2.68 (±0.5) | 2.48 (±0.4) |
Baseline CASE-t | 138.5 (±18.1) | 156.5 (±10.2)e | 10.1 (±6.9) | 5.5 (±4.3)f |
Patient (end of study) | ||||
Readmissions daysg | 5.0 (±5.4) | 4.1 (±4.5) | 3.3 (±4.7) | 5.2 (±5.2) |
n (%) | n (%) | n (%) | n (%) | |
Progressive disease | 2 (9) | 3 (15) | 4 (11.4) | 4 (23.5) |
Inpatient (yes) | 5 (22) | 10 (50) | 6 (17.7) | 7 (41.2) |
SD: standard deviation; CASE-t: Cancer Self-Efficacy Scale–transplant.
Responders = scores > 5 above the mean difference; nonresponders = scores > 5 below the mean difference.
Responders = mean difference scores < 0; nonresponders = mean difference scores > 0.
n = 21.
n = 17.
Compared to responders, t = 4.08 (35), p < 0.001.
Compared to responders, t = −2.52 (50), p = 0.015.
Readmission days = number of inpatient days from initial discharge to end of study.